Skip to main content
Yantai Dongcheng Biochemicals Co.,Ltd. logo

Yantai Dongcheng Biochemicals Co.,Ltd. — Investor Relations & Filings

Ticker · 002675 ISIN · CNE100001DP5 LEI · 300300D2L1BPR7N7KU35 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,044 across all filing types
Latest filing 2026-06-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002675

About Yantai Dongcheng Biochemicals Co.,Ltd.

https://www.dcb-group.com

Yantai Dongcheng Biochemicals Co.,Ltd. specializes in the research, development, production, and distribution of biochemical active pharmaceutical ingredients (APIs) and finished dosages. The company is a major global supplier of heparin sodium and chondroitin sulfate, alongside other biochemical products such as Cytochrome C. Its operations have expanded significantly into the field of nuclear medicine, where it focuses on the development and manufacture of radiopharmaceuticals, including diagnostic imaging agents and therapeutic isotopes. The company maintains a comprehensive supply chain serving the cardiovascular, orthopedic, and oncology therapeutic areas, leveraging its expertise in biochemical extraction and purification to provide high-quality medical solutions to international markets.

Recent filings

Filing Released Lang Actions
关于注射用甲磺酸萘莫司他上市申请获国家药品监督管理局受理的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement that the company’s drug marketing application has been accepted by the National Medical Products Administration. It does not present financial statements, shareholder votes, management changes, or other defined report types. Instead, it is a routine regulatory disclosure and compliance announcement. Therefore, it falls into the catch-all “Regulatory Filings” category (RNS).
2026-06-07 Chinese
关于回购公司股份进展情况的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement of the company’s ongoing share buyback program detailing the number of shares repurchased, prices, total funds used, and compliance with exchange guidelines. It is a periodic progress report on the company’s own share transactions (repurchases), fitting the definition of Transaction in Own Shares.
2026-06-02 Chinese
关于为全资子公司提供担保的进展公告
Regulatory Filings Classification · 92% confidence The document is a corporate announcement (“公告”) regarding the progress of the company providing a guarantee to its wholly-owned subsidiary. It lays out guarantee contract terms, limits, and financial data of the subsidiary. It is not an annual or interim report, earnings release, share issue, dividend notice, M&A, board change, or other specialized filing. It represents a regulatory disclosure in the company’s news releases, best fitting the fallback category for miscellaneous regulatory announcements: RNS.
2026-06-01 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions and detailed voting results from the company’s 2026 first extraordinary shareholders meeting (an EGM). It provides the vote counts for each proposal, confirms the percentage approvals, oppositions, and abstentions, and includes legal opinions on the meeting procedures. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-28 Chinese
北京市中伦律师事务所关于烟台东诚药业集团股份有限公司2026年第一次临时股东会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter from Zhong Lun law firm concerning the convening, eligibility and voting procedures/results of the 2026 first extraordinary shareholders’ meeting (临时股东会) of Yantai Dongcheng Pharmaceutical Group. It is not the company’s Annual Report, earnings release, proxy solicitation, or investor presentation; nor is it a stand-alone audit or governance report. Rather, it is a compliance/legal opinion filing accompanying the meeting disclosure. There is no specific category for legal opinions, so by rule it falls into the generic “Regulatory Filings” category.
2026-05-28 Chinese
第六届董事会第七次独立董事专门会议
Board/Management Information Classification · 85% confidence The document is a notice and resolution of an independent directors’ specialized board meeting, detailing meeting convening procedures, attendance and voting results on a related-party transaction. It is a board-level management announcement rather than an earnings release or regulatory filing. This falls under Board/Management Information (MANG).
2026-05-12 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.